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Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors
for BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection, Sigrid Carlsson and Andrew Vickers, invite some
of the world’s key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the
points of view from the invited experts, the Guest Editors summarize the experts’ views and give their own
personal opinions on PSA screening.Introduction
Sigrid Carlsson (Fig. 1a) and Andrew Vickers (Fig. 1b)
Screening for prostate cancer with prostate-specific
antigen (PSA) is controversial. Screening is currently
transitioning from being an all-or-nothing-question, to
finding new ways of individualized testing. However, con-
sensus remains to be reached within guideline groups and
worldwide experts regarding who – and when – to screen,
if at all. In this Q & A, we invite seven of the world’s key
opinion leaders in the field, both proponents and skeptics,
to elaborate on what they believe the current screening
policy should be. The authors have all published widely on
PSA, and comprise a wide variety of experience in areas
such as urology, epidemiology, evidence-based medicine,
and medical decision-making.
Currently, only one guideline group, the United States
Preventive Services Task Force (USPSTF), recommends
against screening for all men [1]. Most other guideline
groups recommend shared decision-making, involving a
discussion of the pros and cons of screening [2]. To aid in
decision-making, some propose using a risk-stratified
approach taking into account multiple factors along with
a PSA measurement [3]. However, the specifics of such an* Correspondence: vickersa@mskcc.org
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ate age limits of screening remain to be defined. Random-
ized screening trials, including the European Randomized
Study of Screening for Prostate Cancer (ERSPC) and the
Göteborg trial [4, 5] have provided evidence that regular
PSA-screening can reduce prostate cancer mortality by
21–44 % at 13–14 years of follow-up; the age groups stud-
ied in these trials were 55–69 and 50–64 years, respect-
ively. Thus, the question remains regarding the screening
of men outside this age range. There is a growing body of
evidence on the benefits of commencing screening in the
mid-40s. While the American Urological Association
(AUA) bases its recommendation on the 55–69 age group
based on the ERSPC results [6], the European Urological
Association recommends a baseline PSA be obtained at
40–45 years of age [7].
Our personal view is that PSA screening should indeed
involve shared decision-making, but we believe the focus
should primarily be on behavior, rather than preference.
For this purpose, we have published a decision-support
tool called the ‘Simple Schema’ [8], which acknowledges
that the majority of harms of screening result from un-
necessary treatment of low-risk disease and therefore fo-
cuses on the importance of active surveillance as the
appropriate, evidence-based management strategy for low-
risk cancer [9–11]. We further believe that PSA screening
should be a risk-stratified approach aimed at detectingle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Fig. 1 Sigrid Carlsson and Andrew Vickers are the guest editors of
BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection. Sigrid
Carlsson (a) is an associate professor of experimental urology with a
PhD in medicine (urology); she has an MPH from Harvard School of
Public Health. Andrew Vickers (b) holds a DPhil in clinical medicine
and specializes in research methodology and statistics. Both editors
have more than 10 years of experience in the study of screening,
early detection, and treatment of prostate cancer and are on staff at
Memorial Sloan Kettering Cancer Center, New York, NY, USA
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only a small proportion of men with moderately ele-
vated PSA have aggressive disease [5] and that overdi-
agnosis is strongly influenced by age and PSA levels.
For instance, we have shown that almost half of the ex-
cess incidence of cancer associated with PSA testing oc-
curs in men over 70 [12] – a group in which screening
is likely of little, if any, benefit [5, 13] – and that the ef-
fects of screening men in their 60s is highly dependent
on their PSA level, with an excellent ratio of harms to
benefits in patients with PSA ≥2 ng/mL but zero benefit
in patients with a lower PSA [14]. Therefore, the current
guidelines in place at Memorial Sloan Kettering Cancer
Center restrict screening in men over 60 to those with
above average PSAs and dramatically restrict screening in
men over 70 to a small number of men with exceptional
health and high PSA [15]. Additionally, biopsy is recom-
mended only after a repeat PSA and further work-up, and
the frequency of screening is stratified depending on
baseline PSA, which has been shown to be a very strong
predictor of long-term prostate cancer metastasis and
death [16–18].
We were interested in hearing the experts elaborate on
these nuances of screening as we believe this would help
us forward in striving to identify the group of men who
might benefit from screening and those who might not.
Who and when to screen, and not to screen, for
prostate cancer: the proponents’ view
We asked these authors, generally perceived as proponents
of prostate cancer screening, what they think current pol-
icy for prostate cancer screening should be. We then asked
some follow-up questions.
Michael Leapman (Fig. 2), Peter Carroll (Fig. 3),
and Fritz Schröder (Fig. 4)
A Vickers and S Carlsson: You have generally been
perceived as proponents of prostate cancer screening.
What do you think current policy should be; should all
men be screened regardless of symptoms, age, and
baseline PSA levels? Justify your answer with reference
to the literature.
M Leapman & P Carroll: Prostate cancer is a highly
prevalent disease that exhibits considerable variation in
clinical behavior; some men will enjoy long lives with low-
Fig. 2 Michael Leapman, MD, is currently a urologic oncology fellow
at the University of California, San Francisco. He completed his urology
residency at the Mount Sinai Hospital in New York. His research interests
are in developing novel risk prediction tools in early stage
prostate cancer
Fig. 3 Peter Carroll, MD, MPH, is the Ken and Donna Derr-Chevron
Distinguished Professor and Chair of the Department of Urology at
the University of California, San Francisco. Dr. Carroll is a recognized
leader in the field of prostate cancer and urologic oncology, and has
authored or co-authored over 500 publications. His main research
interests include identifying clinical and pathologic determinants
of prostate cancer recurrence, progression, and mortality, discovering
novel biomarkers for prostate cancer diagnostics and prognostics,
developing evidence-based guidelines for improved management
of prostate cancer patients, and examining the impact of lifestyle
on health-related quality of life and survivorship among men with
prostate cancer
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smaller number may succumb to a devastating metastatic
burden. Therefore, the current challenge faced in the early
management of prostate cancer is to identify and treat dis-
ease in men likely to obtain benefit while sparing unneces-
sary detection and, most importantly, treatment in those
who will not.
Compelling randomized evidence suggests that PSA
screening of asymptomatic men is associated with a
significant reduction in death from prostate cancer.
The recent 13-year update of the ERSPC trial, a
multi-centered study examining prostate cancer mor-
tality among participants aged 50–74 receiving regular
PSA screening compared with no routine screening,
has demonstrated a relative risk of death from pros-
tate cancer of 0.79 (95 % CI, 0.69–0.91, P = 0.001) in
favor of screening men aged 55–69 years. Moreover,
when adjusting for non-participation, the reduction in
risk increased to 27 % (95 % CI, 0.61–0.88, P < 0.0007)
[5]. Naturally, screening can only reduce mortality byeffecting treatment of clinically significant disease, as
was observed in the ERSPC experience, in which sub-
stantially more cancers were diagnosed and subse-
quently treated [19].
It is true that eliminating PSA screening will obviously
decrease the number of ‘insignificant’ prostate cancer
cases detected; however, this would come at the impru-
dent expense of ignoring disease in intermediate and
high-risk patients who may stand to benefit substantially.
Indeed, the rationale for treatment in appropriate pa-
tients is redoubled by randomized evidence suggesting
improvement in survival and metastatic progression with
timely treatment of threatening cancers [20]. However,
an overall improvement in prostate cancer mortality is
alone insufficient to justify expansive screening and
treatment of all men if such a strategy will expose those
harboring non-lethal tumors to a non-trivial risk of ad-
verse quality of life outcomes; one should not screen if
overdiagnosis is followed by overtreatment [21].
Fig. 4 Fritz Schröder is Professor of Urology at the Erasmus Medical
Center, the Netherlands. He was international coordinator of the ERSPC
and led the development of the Société Internationale D’Urologie (SIU)
decision aid for PSA testing
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tion may not truly be cast in a monochromatic decision
palette, namely to screen with PSA or not to screen. Ra-
tional practices including the screening of healthy men
with a long life expectancy starting at age 45, cessation of
screening in those with significant co-morbidity and those
of advanced age, extending the interval of screening in
most men (2–4 years), and discontinuing screening for
those with low-risk profiles at certain ages alone would
significantly improve the efficiency of early detection. In
addition, nuanced strategies for prostate cancer detection
and management represent an auspicious frontier. Al-
though not validated in randomized trials of screening
techniques, assays incorporating novel PSA isoforms –
including the 4-Kallikrein panel [22] and the Prostate
Health Index [23] – appear to add much needed specifi-
city for the detection of high-grade (Gleason ≥7) prostate
cancer at a diagnostic prostate biopsy, thereby potentially
reducing the number of unnecessary biopsies performed.
Advanced imaging modalities, including multi-parametricMRI, may also better refine the candidacy and yield of bi-
opsy [24]. Among newly diagnosed patients, tumor-based
risk stratification methods [25] and favorable long-term
experiences with active surveillance [10] are poised to im-
prove the confidence and quality with which incidental tu-
mors are managed. Such measures, being currently
clinically implemented, are highly promising means to
cultivate better screening; these methods will highlight
prostate cancer requiring attention while disregarding
or proposing active surveillance of those that do not.
F Schröder: In my view, the time for population-
based screening has not come and may never do so. The
main reason for my pessimistic view on this issue is the
high probability (of approximately 40 %) of diagnosing
cancers which will not progress clinically, cause symp-
toms, or lead to death (overdiagnosis) [5]. While there
are methods available to decrease overdiagnosis, such as
the use of risk calculators and multiparametric MRI of
the prostate, these have not been sufficiently validated in
multicenter use to establish their accuracy in routine
clinical practice. As a main contributor and former
principal investigator of the ERSPC screening trial, I am
delighted to see increasing worldwide acceptance of the
recommendation of our group, including in US,
European, and Russian guidelines to apply ‘shared
decision-making’. We recommend the use of a proced-
ure developed on the basis of ERSPC data, which is
freely available on the website of the SIU [26].
A Vickers and S Carlsson [to M Leapman and P
Carroll]: Could you please clarify what you think
current policy should be and whether all men should
be screened?
M Leapman & P Carroll: On the basis of randomized
screening trials, PSA screening should be offered to healthy
individuals without known risk factors for prostate cancer
beginning at age 45 [5, 27]. No stark policy, however, will
account for the complexities involved with screening and
early diagnosis of prostate cancer. As a result, screening of
asymptomatic men should be approached in the setting
of a shared decision between a patient and physician
cognizant of the individual’s age, health status, personal
preferences, and risk factors including family history,
race, prior PSA, and biopsy status. As noted above, the
efficiency of screening can be improved and contem-
porary screening guidelines are incorporating refine-
ments as suggested [28].
A Vickers and S Carlsson: You say that “discontinu-
ing screening for those with low baseline risk profiles
[would] significantly improve the efficiency of [PSA]
screening”. Could you give a specific example of the
profile of a man for whom screening should be
discontinued?
M Leapman & P Carroll: Obviously, those in poor
health or of advanced age do not benefit from early
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has not been explicitly compared in a randomized fashion,
but screening at 2–4 year intervals appears appropriate in
low-risk patients based on PSA levels. Baseline PSA status
may offer a valuable insight into a patient’s further risk for
harboring or developing significant prostate cancer. Per-
suasive evidence from a Swedish population-based cohort
examining PSA levels at age 60 suggests that men with
levels <1 ng/mL possess a low (near zero) risk of prostate
cancer death in extended follow-up [14, 17]. It would be
reasonable to forego further screening of a 60-year-old
without other known risk factors with baseline PSA <1 in
the absence of cause.
A Vickers and S Carlsson: You mention various
methods to improve the risk benefit ratio of PSA
screening, including restricting screening in older
men, greater use of active surveillance, and discontinu-
ing screening for some men at low risk. Do you think
it will actually be possible to shift clinical practice in
this way? For instance, radiation oncologists have a
huge financial incentive to treat rather than send a
patient back to the urologist for active surveillance. Do
you think we can get radiation oncologists to use
active surveillance routinely in low-risk patients? How
can we actually get primary care physicians to screen
the right men and avoid screening the wrong men?
M Leapman & P Carroll: It is true that specialists of
all types may have financial incentives to treat, a rela-
tionship that has been used to publically challenge prac-
tice patterns [29]. A more optimistic view of the primacy
of sound clinical practice may be offered by encouraging
trends in the state of Michigan, where nearly half of all
patients diagnosed with low-risk disease are initially
managed with active surveillance [30]. However, who
should be entrusted with the stewardship of screening
and early detection on a population level? Primary care
physicians far outnumber urologists, yet may lack ex-
pertise in the subtleties of the disease. Clear and concise
policy statements as well as better engagement and
education of primary care physicians are essential in
the faithful implementation of such a public health
strategy, and should be coupled with close participation
of specialists when warranted.
A Vickers and S Carlsson [to F Schröder]: You
state that the data do not support “population-based
screening”. The meaning of this term is not entirely
clear. It could be interpreted as “every man getting a
PSA test irrespective of preference”, in which case,
few would disagree with you: is there anyone who is
proposing mandatory PSA testing?
F Schröder: ‘Population-based screening’ has been in-
troduced for several cancers in several countries. It al-
ways includes an offer to a risk group (e.g. men, persons
of certain ages) and indicates an ‘offer’ that allows theperson to be potentially screened to decide. No one pro-
poses ‘mandatory screening’.
AVickers and S Carlsson: Your recommendation ap-
pears to be for shared decision-making. But what is
the exact policy recommendation here? Is it that all
men should be approached (e.g. at 50 or 55) and asked
if they want to consider PSA testing? Or should this
discussion only take place if initiated by the patient?
F Schröder: The application of screening tests will al-
ways occur through patient initiative. Healthcare policy
makers have, in my view, the duty to draw attention to
testing which provides proven health advantages. The
candidate can then decide by establishing a personal
view matching the potential advantages and harms.
A Vickers and S Carlsson: You recommend the use
of a specific decision aid published by the SIU. Is
your vision that this should be given to all men who
are of PSA-screening age?
F Schröder: High quality decision aid instruments
should be freely available and easily accessible in many
languages, but not given without request. Such a proced-
ure would exert some unwanted pressure on persons at
risk. The SIU decision aid [26] is only an example.
A Vickers and S Carlsson: The section of your deci-
sion aid aimed at patients is non-quantitative, listing
various advantages and disadvantages (e.g. cure a treat-
able cancer vs. unnecessary treatment of indolent dis-
ease). However, any course of action has pros and cons.
If I choose to go for a walk right now, the advantage is
that I get some fresh air and exercise and the disadvan-
tage it that I might get shot. I can't make a decision
about whether to go for a walk unless I know my risk of
being killed (compare living in a peaceful area versus a
war zone). More specifically, imagine it were the case
that a terrific new marker was discovered as a reflex test
that had 99 % specificity and sensitivity for lethal dis-
ease. None of the wording on the decision aid would
change (there is still a risk of unnecessary treatment
and a risk of false reassurance). How is a patient meant
to weigh these pros and cons without some idea of risk?
F Schröder: Weighing pros and cons of a medical
procedure will always remain the responsibility of the
person at risk. We, as doctors and urologists, have to
help by addressing the questions arising after reading
the first section of the decision aid, which is only one
page. The two other sections are meant for the health
professional. My personal view is that the pros and cons
which are relevant to potential patients should be made
widely accessible using all currently available evidence
and instruments.
A Vickers and S Carlsson: The decision aid is 20
pages long. Is it realistic to expect primary care physi-
cians to read and remember so much information (e.g.
rate of discomfort during biopsy of 55 %)?
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physician is held very short for the reasons given. The ur-
ologist has to have a deeper insight in preparation of
shared decision-making with potential patients.
Who and when to screen, and not to screen, for
prostate cancer: the skeptics’ view
We asked these authors, generally perceived as skeptical
about prostate cancer screening, what they think current
policy for prostate cancer screening should be. We then
asked some follow-up questions.
Peter C Albertsen (Fig. 5) and Dragan Ilic (Fig. 6)
A Vickers and S Carlsson: You have generally been
perceived as an individual who is skeptical about
prostate cancer screening. What do you think current
policy should be; should there be no screening ever?
That is, should PSA be avoided entirely inFig. 5 Peter C Albertsen is chief of urology and residency program
director at the University of Connecticut Health Center in
Farmington, CT. His research interests have focused on
understanding the natural history of prostate cancer and the
impact of treatment on health-related quality of life. He has
published widely in the field of outcomes research in prostate
cancer, including the impact of screening for prostate cancer.
He is a past trustee of the American Board of Urology and has
served as President of several national urological societies
Fig. 6 Dragan Ilic is Associate Professor of Evidence Based Clinical
Practice at the Department of Epidemiology and Preventive
Medicine, School of Public Health and Preventive Medicine, Monash
University, Australia. He is a member of the Cochrane Urology
review group and co-author of the Cochrane systematic review
‘Screening for Prostate Cancer’asymptomatic men, or should screening be restricted
to certain subgroups and, if so, whom? Justify your an-
swer with reference to the literature.
P Albertsen: Few cancers generate as much contro-
versy as prostate cancer concerning screening, diagnosis,
and treatment. From 1977 to 2005, the lifetime risk of
prostate cancer diagnosis in the US increased from 7.3 %
to 17 % [31, 32]. During this same period, the lifetime risk
of dying from prostate cancer fell from 3.0 % to 2.4 %.
My views on prostate cancer screening and treat-
ment have been shaped by my training in urology at
Johns Hopkins and epidemiology and public health
at the University of Wisconsin, as well as by my pa-
tients. One patient in particular had a powerful in-
fluence. He was referred for treatment of a localized
prostate cancer and underwent successful surgery.
His postoperative PSA was undetectable and all sur-
gical margins were negative. I told him he was cured
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spread metastases. I treated him successfully with
anti-androgen therapy for an additional 16 years. Ac-
cording to the Halsted model of cancer progression
he should have been cured by surgery [33]. I had the
original specimen re-cut to document negative margins
and concluded that we had a poor understanding of
the natural history of this disease and the efficacy of
treatment.
To address this problem, I developed a Markov model
of prostate cancer progression. With the assistance of
Jack Wennberg’s research group, the model was pub-
lished in JAMA [34]. At the time, it was severely criti-
cized by the urologic community, but when reviewed
today the model bears a remarkable resemblance to data
recently published by the SPCG-4 [35]. The sensitivity
analysis indicated that data concerning the natural his-
tory of this disease was most critical to estimating the
relative value of intervention. This is why I gathered data
on the natural history of this disease from patients en-
rolled in the Connecticut tumor registry and published
them in JAMA in 1998 and 2005 [36, 37].
My training in epidemiology taught me to view health-
care delivery from a public health perspective. Screening
programs were best assessed by addressing four key ques-
tions: (1) Is prostate cancer a suitable disease for screen-
ing? (2) Is treatment for prostate cancer effective? (3) Is
PSA an effective screening test for this disease? (4) Does
screening result in any harm?
Early detection and treatment for prostate cancer is not
a new idea. As early as 1905, Hugh Hampton Young sug-
gested that a careful digital rectal examination could iden-
tify changes in prostate gland texture that could lead to
the early diagnosis of cancer and appropriate intervention
[38]. Only recently have we begun to appreciate that a
large number of men harbor indolent disease, as clearly
demonstrated by data from the Finasteride Chemopreven-
tion trial [39]. Many pathologists now question whether
Gleason 3 + 3 tumors are sufficiently aggressive to cause
morbidity [40]. Indeed, recent data from the ERSPC
trials suggest that half of all screen-detected cancers
are indolent [5].
The efficacy of treatment also poses problems. Most
urologists and radiation therapists assume that surgery and
radiation are curative. However, what do the data say? The
SPCG-4 suggests that some men are cured by surgery, but
many men are not [35]. Further, men with high-grade dis-
ease often die from prostate cancer despite surgery and
that surgery is primarily palliative for men aged over 65.
With regards to radiation, even less information concerning
its efficacy is available to date.
How well does PSA perform as a screening tool? Un-
fortunately, many lethal tumors produce low amounts of
PSA and are missed by screening studies. Additionally,prostate enlargement, prostatitis, and surgical manipula-
tion can lead to a significant number of false positive
values. Finally, screening can result in considerable mor-
bidity as documented by the USPSTF report [1].
Do I believe that PSA testing should be abandoned? Of
course not, screening clearly benefits some men. This is
why I helped draft and support the prostate cancer screen-
ing guidelines approved by the AUA [6]. Unfortunately,
most clinicians focus primarily on the potential benefits of
screening in individual patients and downplay the harms
associated with testing as measured from a public health
perspective. Before we can advocate for population-based
screening, we must understand the natural history of the
disease identified by testing and gain a better appreciation
of the efficacy of treatment. This is why I have been an ad-
vocate of active surveillance for men with low-grade dis-
ease [9]. Data from the ProTECT trial should provide
important new data concerning efficacy when published
in the spring of 2016 [41]. Ideally, screening should only
identify men destined to suffer from clinically significant
disease and patients should only be offered treatments
that yield substantial benefit. We still have a long way to
travel to reach this goal.
D Ilic: Prostate cancer is a leading cancer affecting men
worldwide [42]. Despite its high prevalence, the current
evidence suggests that screening asymptomatic men for
prostate cancer is not warranted [1, 43]. The most recent
Cochrane systematic review identified five randomized
controlled trials examining the effectiveness of screening
[43]. A meta-analysis of data from those five trials deter-
mined no significant difference in prostate cancer mortal-
ity between men randomised to screening in comparison
to those who were not (risk ratio (RR) = 1.00; 95 % CI,
0.86–1.17) [43].
Only two of the five randomized controlled trials in-
cluded in the 2013 systematic review were determined
to methodologically present a low-risk of bias [43]. The
point of interest lies in the differing results and conclu-
sions offered by two studies: the ERSPC and the Prostate,
Lung, Colorectal and Ovarian (PLCO) cancer screening
trial [27, 44]. The ERSPC study was the only study, out of
the five included in the meta-analysis, to demonstrate a
reduction in prostate cancer mortality from screening
(RR = 0.84; 95 % CI, 0.73–0.95) [27]. Conversely, the
PLCO study reported no benefit in screening (RR = 1.15;
95 % CI, 0.86–1.54) [44]. Criticisms of both the ERSPC
and PLCO studies exist. The PLCO study has been criti-
cized for the large number of participants entering the
trial with a history of screening and the level of contamin-
ation by control participants continuing to be screened
[43, 45, 46]. The ERSPC study has been critiqued for the
variation in study protocols and their implementation
across study sites [43, 46]. In 2014, the ERSPC published
13-year follow-up data, reporting a 21 % reduction in the
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0.79; 95 % CI, 0.69–0.91) [5]. A sub-group analysis of
prostate cancer mortality by age at randomization identi-
fied a significant decrease in prostate cancer mortality in
the 65–69 year age group (RR = 0.69; 95 % CI, 0.55–0.87).
No statistically significant difference in prostate cancer
mortality was observed between screening and control
groups in men aged <54, 55–59, and 60–64 years [5]. The
results also suggest that screening is not beneficial in men
aged over 70 years (RR = 1.17; 95 % CI, 0.82–1.66). The
ERSPC study authors concluded that, “…the time for
population-based screening has not yet arrived…” [5].
Given that the current evidence does not support
population-based prostate cancer screening, the ques-
tion then turns to screening on an individual basis.
For individual patients to make an informed decision,
they must be aware of the benefits and harms associ-
ated with the diagnostic tests used when screening
for prostate cancer. The PSA test is used as the com-
mon frontline test for prostate cancer; nevertheless,
its sensitivity and specificity, as reported in the litera-
ture [47], varies widely. The potential for high false
positive and significant false negative rates with PSA
testing can lead to substantial harms, including over-
diagnosis and overtreatment [1, 43, 47, 48]. Identifying a
cancer that would never have become apparent in the ab-
sence of screening and then subjecting the patient to inva-
sive treatment can lead to significant physical, emotional,
and psychosocial harms [1, 43].
Age, family history, and ethnicity have been determined
as risk factors for prostate cancer [49]. Whilst there is no
evidence to support population-based screening, patients
and clinicians should discuss the potential benefits and
harms of screening as it relates to the individual patient
[1, 43]. The use of decision aids and risk calculators can
increase patients’ knowledge and decision-making to en-
sure that patients and clinicians engage in an informed,
evidence-based decision grounded on the patient’s needs
and circumstances [50].
A Vickers and S Carlsson [to P Albertsen]: You
argue that, “before we recommend ‘population-based
screening’ we must understand the natural history of
the disease identified by testing and gain a better
appreciation of the efficacy of treatment.” Can you be
a little bit more specific?
What are the precise gaps in our understanding of
the natural history of prostate cancer that prevent us
from developing optimal screening programs?
What research, exactly, must be performed to address
these gaps? What are the specific gaps and associated
research studies that need to be carried out as regards
treatment efficacy?
P Albertsen: For a screening program to be successful
from a public health perspective (i.e. population-basedscreening) three critical issues must be satisfied: (1) the
disease in question must pose a significant health burden,
(2) the screening tool must be able to identify the disease
sufficiently early in its natural history so that outcomes
can be altered, and (3) a treatment must exist that can
alter the outcome of the disease identified by screening.
Many urologists believe that PSA testing satisfies these
criteria; unfortunately, it does not – neither when it was
proposed in the late 1980s, nor now.
PSA screening does increase the likelihood of finding a
condition termed prostate cancer, but it does not dis-
criminate between a disease representing a significant
health burden and one that is essentially indolent. As
noted in the most recent report by the ERSPC, approxi-
mately half of the cancers identified by PSA testing are
Gleason 6 and are not destined to pose any significant
clinical burden [5]. We also know that PSA testing
among older men is unlikely to identify clinically signifi-
cant disease in many men, yet most screening appears to
be done in this age group [51]. The Finasteride Chemo-
prevention trial has provided critical information on the
widespread prevalence of low-grade prostate cancer and
the PIVOT trial and the SPCG-4 trial have provided
much needed information on the natural history of pros-
tate cancer [35, 52, 53] The ProTECT trial should add
to this critical data when reports are published next year.
While many of us recommend active surveillance for
men with Gleason 6 disease, most of these men are still
receiving aggressive interventions that often do more
harm than good.
Finally, the third criterion is equally important. Most
urologists assume that a radical prostatectomy is cura-
tive; nevertheless, data to support this assertion are
missing. Currently, the best data have arisen from the
SPCG-4 trial, which demonstrates that most men with
high-grade disease do not benefit from surgery [35].
Prostate cancer mortality is similar for men undergoing
surgery and those undergoing delayed androgen sup-
pression. Surgery does appear to benefit men with
intermediate-grade disease, but this is seen primarily
among younger men rather than those aged over 65. It
could be that the study investigators did not identify
men sufficiently early during the course of their disease;
however, the PIVOT trial has also raised questions re-
garding the efficacy of surgery [53], thus highlighting the
importance of the ProTECT trial. Unfortunately, we
have even less information concerning the efficacy of ra-
diation in any of its forms [41].
What are the gaps in our understanding of the natural
history of prostate cancer? We need a tool that can
clearly indicate whether a man has a disease that will
cause significant morbidity and death during his natural
lifetime. We also need randomized trials that demon-
strate how well our primary treatments, namely surgery
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tate cancer. There is no substitute for this information.
A Vickers and S Carlsson: One of the problems with
waiting for new data is that it is rarely as definitive as
anticipated. You say that the “ProTECT trial should
provide important new data” in 2016, but that will be
pretty early data – only 10 years of follow-up – and
does not reflect best practice: a single PSA when a man
is in his 50s or 60s, surgery from low-volume surgeons,
and relatively low-dose radiotherapy. As regards the
treatment trial in ProTECT, about three quarters of
patients have low-grade disease, which we now believe
should not be treated at all. Do you really think
that ProTECT will provide enough data about screen-
ing and treatment to move forward with practice
recommendations?
P Albertsen: We currently have practice recommen-
dations from the AUA that focus PSA testing on the
group of men most likely to benefit. While I agree that
research trials are rarely as definitive as anticipated, each
new study helps refine our understanding of the efficacy
of screening and treatment. The ProTECT study will
publish 10-year data next year. I agree that this is a rela-
tively short follow-up, but it is 10 years ahead of any
randomized trial being conducted in the US. You state
that the trial does not reflect best practice, but how can
you be sure that PSA testing, as currently practiced in
the US, is best practice (see response to question #1).
You dismiss the trial because it is being conducted by
‘low-volume surgeons’. What evidence do you have that
surgery is less efficacious among low-volume compared
to high-volume surgeons? These surgeons know how to
operate and have undergone quality assurance compari-
sons as part of the trial. Is that also true for high-volume
surgeons in the US? Imagine that the high-volume sur-
geons had participated in a similar trial when PSA
testing became widely adopted in the US. If this had
been the case, we would now have a completed trial
with a large sample size and 20-year follow-up. The
UK government would rather invest in clinical trials
to determine if screening and treatment works, than
simply pay for surgery and radiation that urologists/
radiation therapists claim has a major impact. Finally,
I would be surprised to learn that three-quarters of
the men enrolled in the trial have low-volume, low-
grade disease. These men are usually identified fol-
lowing repeated PSA testing. Let’s review the results
together in 2016. Without the European trials, includ-
ing SPCG-4, ERSPC, and ProTECT, we would only be
left with the PIVOT and PLCO data [54]. How would
urologists debate prostate cancer screening and treat-
ment with these data? You seem to advocate crafting
screening and treatment policies with the hope that
the tools and treatments work. I am a bit more skepticalgiven the history of breast cancer screening and man-
agement and that of other medical theories that have
been discarded.
AVickers and S Carlsson: You say that “many lethal
tumors … are missed by screening”. We all know that
does sometimes occur, but do you have any good
estimates as to how common it is? The Malmö
studies suggest that the incidence of lethal disease in
men with low PSA is actually extremely low.
P Albertsen: I agree with your statement that the inci-
dence of lethal disease in men with low PSA is extremely
low. I also believe that the incidence of high-grade, lethal
prostate cancer, is also very low in general. This latter
statement carries significant implications on the perform-
ance of a screening test. When the incidence of the condi-
tion you are searching for is low and the pool of potential
patients is very large, test performance becomes critical –
false positives rapidly overwhelm true positives. You can
reassure most men in their early 50s and even 60s that
they will not die from prostate cancer in the absence of
PSA testing and be right 97 out of 100 times because the
lifetime risk of dying from prostate cancer is approxi-
mately 3 %. Unfortunately, we have all seen the young
men in their 50s who present with Gleason 8–10 tumors
and have extra prostatic extension by the time they
undergo surgery. As a clinician, I wish we could find these
tumors earlier and cure these men. As someone trained in
epidemiology, I know that the ability to achieve this dream
is very difficult, especially when the tests have modest sen-
sitivity and specificity and the treatments are moderately
effective (see responses to Questions 1 and 2) [1].
AVickers and S Carlsson: The original question asked
“Should PSA be avoided entirely in asymptomatic men,
or should screening be restricted to certain subgroups
and, if so, whom?”. You seem to agree with the latter:
you say that screening should not be abandoned
because it “clearly benefits some men”. So which men
should be screened?
P Albertsen: Based upon what we know in 2015, PSA
testing does benefit some men. For this reason I strongly
support the recommendations of the AUA. These guide-
lines were based extensively on the data provided by the
ERSPC. However, we need to do better. I am aware of
your work with Hans Lilja, suggesting that a PSA value at
age 50 is predictive of the long-term probability of devel-
oping clinically significant prostate cancer [18]. I believe
we can refine the group of men who should be tested. We
also need to incorporate the natural increase in PSA that
comes with prostate enlargement that occurs when a man
ages through his 50s and 60s. A graphic chart that tracks
PSA levels or, possibly, percent free-PSA or the new pros-
tate health index test against age and prostate volume,
similar to a pediatric growth chart, might be helpful. Men
consistently falling outside the 90th percentile, for
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prostate biopsy. All of these refinements should be aimed
at lowering the incidence of low-volume, low-grade
cancer. In my mind, we have yet to define a best practice
screening and treatment algorithm. While the AUA rec-
ommendations are a start, we have not agreed upon the
test(s) needed, the frequency of their application, the value
of imaging versus biopsies, nor on which treatments work
best for which patients. These are the research gaps that
should be addressed by trials. Unfortunately, these trials
are often difficult to conduct in the US because of per-
verse economic incentives and clinicians who are con-
vinced that current practices are the preferred standard
of care.
A Vickers and S Carlsson [to D Ilic]: You seem to
base your conclusions on the Cochrane meta-analysis.
However, as you mention, three of the studies were as-
sociated with a high-risk of bias. Moreover, one of
these studies did not even include PSA screening until
very late in the trial. Do you think it is valid to report a
risk ratio from a combined analysis including poor
quality studies?
D Ilic: The meta-analysis of all five studies provides a
broad overview of the evidence available on the topic. The
Cochrane review cited provides a sensitivity analysis in
which these poor quality studies are removed and their
impact upon the overall meta-analysis can be identified.
It is interesting to note that, even following their re-
moval, the sensitivity analysis with the two ‘good’ qual-
ity trials was not greatly affected (RR = 0.96; 95 % CI,
0.70–1.30 (‘good quality trials’) vs. RR = 1.00; 95 % CI,
0.86–1.17 (‘all trials’)) [43].
A Vickers and S Carlsson: You imply that the key
consideration is to compare the results of the PLCO
and ERSPC studies. These studies addressed very dif-
ferent study questions. The ERSPC was a trial of
screening versus no screening; the PLCO was explicitly
described by the investigators as a trial of ‘systematic’
vs. ‘opportunistic’ screening. Would we expect these
studies to have results that are in any way comparable?
Do you think it makes sense to combine the results
meta-analytically? By way of analogy, if we had a trial
of aspirin vs. no aspirin for pain, and another trial of
systematic aspirin vs. aspirin as needed, do you think
we could combine the trials to get an estimate for
aspirin effectiveness?
D Ilic: The aim of performing a meta-analysis with
these two studies is to increase the power, improve preci-
sion, and hopefully have the evidence to answer such a
controversial question. In performing a meta-analysis,
careful consideration is given to the impact of clinical,
methodological, and statistical heterogeneity upon the
outcome [55]. The PLCO study has been described as out-
lined above, partly due to the high rate of contaminationreported and the potential for such contamination to
mask any clinical benefit from screening. Methodological
heterogeneity has been reported for the ERSPC study,
with significant variation amongst study sites with respect
to screening protocol, contamination, and follow-up [5].
In performing a meta-analysis of these studies, the as-
sumption is that their objectives, study design, partici-
pants, interventions, outcomes measured, and follow-up
are sufficiently homogeneous to allow the pooling of data.
A Vickers and S Carlsson: You say: “No statistically
significant difference in prostate cancer mortality was
observed between screening and control groups in
men aged less than 54, 55–59, and 60–64 years”.
What conclusion do you draw from that?
D Ilic: The rate ratios (RR) for the respective age
groups are as follows, <54 (RR = 0.84; 95 % CI, 0.28–
2.49); 55–59 (RR = 0.81; 95 % CI, 0.93–1.03); and 60–64
(RR = 0.90, 95 % CI, 0.71–1.15). These results would in-
dicate that there is no evidence to support the hypoth-
esis that screening significantly reduces the risk of
prostate cancer mortality in these groups. For example,
the risk ratio and confidence intervals for the <54 age
group indicate great variability for the potential of
benefit and harm as a result of screening. It should be
noted that the AUA recently modified their guideline
recommending against PSA screening in men under
40 years of age, and in men aged 40–54 years at average
risk. For men aged 55–69 years, a shared approach to
decision-making was advocated [56].
A Vickers and S Carlsson: You state that “patients
and clinicians should discuss the potential benefits
and harms of screening as it relates to the individual
patient” and then cite two papers: your own review
showing no benefit to screening and the USPSTF
report that explicitly stated that there was a reasonable
degree of ‘certainty’ that screening does more harm
than good. So what should clinicians tell patients about
the harms and benefits of screening?
D Ilic: Clinicians should refer to the ERSPC and
PLCO studies, and their various strengths and limita-
tions. The potential benefit of screening (as reported by
the ERSPC) is a reduction in prostate cancer-specific
mortality (0.11 per 1,000 person-years, or one prostate
cancer death averted for every 781 men invited for
screening) [5]. The PLCO study (and others) would
suggest no reduction in prostate cancer mortality from
screening. Potential harms include overdiagnosis, im-
plications of false-positive test results, adverse events
from further testing including hematospermia, hematuria,
infection, bleeding, urinary difficulties and anxiety [1, 43,
56]. Such detailed information can be difficult to convey
to patients in a short period of time during a consult-
ation – hence the need for greater use of decision aids
and other patient education strategies to ensure that
Fig. 7 Michael Barry is president of the nonprofit Informed Medical
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He is a past president of the Society for Medical Decision Making and
the Society of General Internal Medicine in the US. He has led many
prominent research studies including the Patient Outcome Research
Team for Prostatic Diseases. He continues to practice primary care and
serves as medical director of the John D. Stoeckle Center for Primary
Care Innovation at Massachusetts General Hospital. He is also a part
time professor of medicine at Harvard Medical School and a Master of
the American College of Physicians
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screening.
A Vickers and S Carlsson: You cite a review on the
operating characteristics of PSA to suggest that its
sensitivity is questionable. This review used the
presence of prostate cancer as an endpoint. Many
would argue that it is rather irrelevant whether PSA
has good or bad sensitivity for prostate cancer, because
most prostate cancer is indolent. The key question is
whether PSA is sensitive for potentially lethal disease.
What is your view on whether PSA is a good predictor
for aggressive prostate cancer?
D Ilic: The PSA test is currently the frontline test
that clinicians rely on with respect to diagnosing pros-
tate cancer. However, the PSA test is problematic in
distinguishing whether the cancer will become lethal in
men diagnosed with localized prostate cancer. The PSA
test has been demonstrated to be a poor predictor for
detecting lethal prostate cancer, as evidenced by men
who have been diagnosed with localized prostate cancer
and managed by watchful waiting [57]. Modifying exist-
ing strategies for using the PSA test, such as interval
times and thresholds for biopsy, have been proposed,
although greater emphasis is currently placed on the
development of new markers that could differentiate
between indolent and potential lethal cancers [49].
Who and when to screen, or not to screen, for
prostate cancer: the decision-analytical view.
Don’t throw the baby out with the bathwater
We asked these authors, involved in implementing shared
decision-making in primary care, what they think current
policy for prostate cancer screening should be. We then
asked some follow-up questions.
Michael Barry (Fig. 7) and Dominick Frosch (Fig. 8)
A Vickers and S Carlsson: You are involved in
implementing shared decision-making in primary care.
What do you think current policy regarding PSA
screening should be? Do you think that all men should
be screened, should there be no screening at all, or
should PSA testing be restricted to certain groups? If
so, whom? Justify your answer with reference to the
literature.
M Barry and D Frosch: In the early days of the devel-
opment of clinical practices guidelines, Dr. David Eddy
emphasized the importance of including the perspective
of informed patients in the guideline development
process. For example, a standard for or against an inter-
vention would require that, “…at least 95 %, perhaps
even 99 %, of people who are candidates for the interven-
tion should agree on the desirability [or undesirability] of
its outcomes” [58]. Current evidence from prostate can-
cer screening trials, in our minds, does not justify a
standard to either ‘screen everyone’ or ‘screen no one’,at least for the pre-specified core group of men aged
55–69 for which a small but finite and statistically
significant reduction in prostate cancer mortality was
found in the ERSPC. In the latest follow-up from the
ERSPC, at a 13-year mean follow-up, PSA screening
reduced the risk of dying of prostate cancer from
0.61 % in the intervention group to 0.49 % in the
control group for men aged 55–69, leading to a sta-
tistically significant 1.28 fewer prostate cancer deaths
for every 1,000 men randomized. On the other hand,
not surprisingly, screening increased the risk of being
diagnosed with prostate cancer, from 6.1 % to 8.0 %.
Moreover, the cumulative risk of a positive PSA test in the
intervention group was about 17 %, with 82 % of these
men receiving a biopsy [5]. This higher risk of prostate
cancer diagnosis comes with considerable overtreatment
with its attendant side effects, particularly of incontinence
Fig. 8 Dominick L Frosch, PhD, is a fellow in the Gordon and Betty
Moore Foundation’s Patient Care Program and associate professor of
medicine at the University of California, Los Angeles. He has conducted
several randomized controlled efficacy and effectiveness trials of patient
decision support for PSA screening and has led efforts to implement
patient decision support in primary and specialty care. He currently
serves as deputy editor for the Journal of General Internal Medicine
Carlsson et al. BMC Medicine  (2015) 13:288 Page 12 of 17and sexual dysfunction, even more so in the US, where
aggressive treatment of prostate cancers is routine. In the
US PIVOT trial comparing radical prostatectomy versus
observation of men randomized to surgery, 17 % had
incontinence at 2 years versus 6 % with observation, and
81 % had erectile dysfunction compared to 44 % with
observation [53].
Different men will see these tradeoffs between bene-
fits and harms differently. Nine efficacy trials indicate
that, when men are fully informed about the benefits
and risks of prostate cancer screening using a decision
aid, interest in the PSA test decreases [50]. However,
even among men who can answer all questions cor-
rectly on a knowledge test about PSA screening, about
a third still want a PSA test [59]. We believe both the
clinical evidence and the equally important evidence
about preference distributions among well-informed
men supports a shared decision-making strategy about
PSA screening for men aged 55–69, as recommended
in the clinical practice guidelines by both the AUA and
the American College of Physicians. Decision aids can
be used to make this approach practical in the busy
world of primary care. Shared decision-making is also
important in making treatment decisions for men who
choose screening and are diagnosed with prostate can-
cer; helping men understand that some form of obser-
vation, including active surveillance, is the optimaltreatment for most PSA detected cancers can help break
the cycle linking prostate cancer overdiagnosis with over-
treatment [60]. Shared decision-making can help avoid
throwing out the baby – and the PSA test – with
the bathwater.
A Vickers and S Carlsson: You make a strong case
that the benefits of PSA testing, in terms of reduced
mortality, do not obviously outweigh the harms, in
terms of overdiagnosis and overtreatment. Specific-
ally, you say that the harms are a particular problem
because “aggressive treatment of prostate cancers is
routine”. Your solution hinges on understanding the
preferences for individual men. Why not focus on
harm reduction instead? By way of analogy, the benefits
of eggs for breakfast is that they are nutritious; the
problem is that I could get egg on my tie. I could do a
‘shared decision-making’ where I consider how much I
like eggs versus how much I care about my appearance.
However, would it not be more effective just to eat more
carefully or only put on my tie after breakfast? Why
not put efforts into reducing overdiagnosis and
overtreatment rather than treating these as a fact of
life (‘routine’ in the US) and then applying preference-
based approaches?
M Barry & D Frosch: Although there is growing rec-
ognition in some quarters that prostate cancer is subject
to substantial overdiagnosis and overtreatment, at present,
it is difficult to conclude that there is consensus on this
issue. Two recent reports paint a conflicting picture of the
use of active surveillance in managing low-risk prostate
cancer. One report, drawing on the US National Cancer
Database, concluded that active surveillance remains sub-
stantially underused [61]. Another report, published one
week later and drawing on the CaPSURE database, con-
cluded that substantial progress has been made increasing
the use of active surveillance [62]. The issue of patient ac-
ceptance of conservative approaches to managing cancer
is further complicated by a long history of promoting can-
cer screening, with slogans such as ‘do not delay’ [63]. As
a result, enthusiasm for cancer screening, and perhaps
treating it aggressively, is higher than warranted among
the general public and a recent study suggests that cancer
screening is viewed as a moral obligation, rather than a
deliberate decision that requires careful consideration of
how the potential benefits and risks of screening align
with individual patient preferences [64, 65]. Furthermore,
the American public is acutely sensitive to any suggestion
that access to medical treatment might be restricted or with-
held. Thus, engaging patients in shared decision-making is
perceived as a palatable approach to reducing overdiagnosis
and overtreatment by sensitizing patients to important nu-
ances of risks and benefits that should enter cancer
screening and treatment decisions. Additional tests that
could reliably distinguish aggressive from indolent cancers
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menting shared decision-making may be challenging, but
changing clinician behavior is no less so. Arguably, at-
tempts to address this problem should ideally focus on
both sides of the equation.
A Vickers and S Carlsson: You say that decision aids
can make shared decision-making “practical in the
busy world of primary care”. Prostate cancer decision
aids have been around for a long time and they are not
widely used. There is also evidence that, whatever their
effect on decisional conflict and regret – two highly
problematic endpoints – decision aids do not improve
shared decision-making [66]. Do you really see a future
where the millions of US men reaching screening age
each year are routinely referred to decision aids before
PSA screening?
M Barry & D Frosch: It is important to recognize that
providing decision aids to patients does not in itself con-
stitute shared decision-making. Rather, these tools are
intended to support a shared deliberative process by help-
ing to inform a patient about the specific potential benefits
and risks of PSA screening [67]. Achieving shared deci-
sion-making requires a physician who is appropriately
trained and willing to engage patients in the necessary de-
liberative process. Making shared decision-making a rou-
tine process ultimately requires a significant cultural shift,
both on the part of practicing clinicians and on that of pa-
tients, who, for the most part, have been socialized into a
paternalistic medical culture. While this cultural trans-
formation is arguably underway, considerable work re-
mains, including systemic transformation of clinical
processes and workflows to enable shared decision-mak-
ing, as well as the development and implementation of
corresponding quality measures [68]. The Cochrane re-
view summarizing all randomized trials of patient decision
aids indeed shows reduced proportions of people who are
passive in decision making when decision aids are used
(summary risk ratio, 0.66; 95 % CI, 0.53–0.81, n = 14 trials)
[50]. A recent systematic review of surveys of patient pref-
erences for participation confirms the growing public de-
sire for shared decision-making. While the majority of
respondents desired shared decision-making in 50 % of
surveys conducted prior to 2000, for surveys conducted
after 2000, this number increased to 71 % [69]. We can
definitely envision a future when millions of patients en-
gage in shared decision-making around cancer screening
with their clinicians, facilitated by the availability of high-
quality decision support. We believe that the translation
of this vision into reality is underway, but considerable
work remains and the path to systemic culture change in
which fateful decisions are made in partnership between
patient and clinician will not always be smooth or linear.
A Vickers and S Carlsson: You cite evidence that use
of decision aids reduces prostate cancer screening rates.This might well be seen as unsurprising given that these
aids were implemented some years ago and long-term
follow-up from ERSPC – perhaps the major reason why
a man might consider PSA – has only just been made
available. Indeed, some decision aids include directly
false statements against PSA. For instance, the decision
aid used in the study by Sheridan et al. [66] stated that
there is no way of telling whether a cancer found by
screening is dangerous or not. Do the lowered rates
of screening following implementation of decision
aids reflect an inherent property of decision aids or
the content of the decision aids currently available
for prostate cancer?
M Barry & D Frosch: Content is important and deci-
sion aids need to be kept up-to-date with the latest
evidence (see comment below regarding decision aid
certification). Nevertheless, whether evolving evidence
regarding the benefits and harms of PSA screening will
change the proportion of men who decide for or against
screening remains to be seen. The absolute risk reduc-
tion in prostate cancer mortality with longer follow-up of
the ERSPC has increased from 0.71 per 1,000 men ran-
domized at 9 years to 1.28 per 1,000 men randomized at
13 years [5, 70]. Whether such an increase in absolute
difference will change many men’s minds, particularly
when the risks are to be faced in the nearer term
compared to the delayed benefits, remains unknown.
Even at 13 years, the ratio of the number of men who
must face a diagnosis of prostate cancer to the attend-
ant risks of treatment remains high, at 27 for each
prostate cancer death averted.
A Vickers and S Carlsson: We have previously
highlighted that current decision aids [8] used
questionable estimates of risk and often disagree
with one another (e.g. one decision aid gives a risk
of overdiagnosis at approximately four-fold to another).
Further, several decision aids are available. Which should
a clinician use?
M Barry & D Frosch: With the proliferation of deci-
sion aids from a wide range of developers, both com-
mercial and academic, there is an urgent need for a
certification process to ensure that decision aids present
comprehensive and valid information [71]. The state of
Washington, which passed legislation in 2007 offering a
higher level of malpractice protection to physicians who
engage patients with certified decision aids, is currently
at the forefront of developing such a process [71, 72].
While this does not solve the immediate problem facing
a clinician choosing a decision aid for patients today, it
is the reflection of an evolving marketplace that is grad-
ually maturing. The Affordable Care Act recognized the
need for a certification process, but thus far the US Con-
gress has not appropriated resources to support its
development.
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aids require that patients integrate up to ten risk
estimates for very different events (including pulmonary
embolism, biopsy symptoms, erectile dysfunction, and
prostate cancer death). Do you think this is feasible for
most patients or only for a small proportion?
M Barry & D Frosch: Over the past several decades,
researchers have developed numerous innovative ways of
communicating risk information to patients with a range
of numeracy and health literacy skills. We believe these
tools can enable us to communicate and integrate com-
plex risk information to a wide range of patients [73].
Some of the risks cited above, such as the risk for pul-
monary embolism, seem more appropriate for decision
aids addressing prostate cancer treatment, rather than
screening. Nonetheless, a rigorous certification process
can help ensure not only that the information provided
is accurate and valid, but that appropriate methods are
used to present the information to maximize under-
standing by patients from a wide range of backgrounds,
including those with lower levels of health literacy and
numeracy.
Discussion
Responses to the Q & A
Sigrid Carlsson and Andrew Vickers
In this Q & A, we asked seven experts who have stud-
ied PSA screening to provide their view on what pros-
tate cancer screening policy should be. Our original aim
was to assess whether a middle ground could be found,
for example, by asking proponents where PSA testing
should be restricted and skeptics where it might be of
value. We believe we were successful in finding this mid-
dle ground. There was unanimity among our respondents
that PSA should not be implemented routinely at the
population level. In contrast to, for example, cervical can-
cer screening, we should not expect a situation where
most individuals in the population at risk would receive a
PSA test as a routine part of care. Instead, all experts agree
that screening should take place only as shared decision-
making between an individual man and a healthcare pro-
vider. There was also unanimity that prostate cancer
screening was associated with important harms and
that increased use of active surveillance for low-risk
disease is required.
With the exception of Dr. Ilic, there was also agreement
that prostate cancer screening does indeed reduce prostate
cancer mortality. We find ourselves critical of Dr. Ilic’s re-
sponse – we did not feel that his response was sufficiently
clear regarding the critical issue of whether it is justified to
combine the PLCO [44] and ERSPC results [5], referring
only to the value of meta-analysis in general. In answering
a question about the proven value of PSA for predicting
long-term risk of lethal disease at the population level, Dr.Ilic rather focused on the value of PSA in men diagnosed
with prostate cancer. Further, some differences in emphasis
were observed; for instance, Dr. Albertsen is clearly more
concerned about the current state of the data compared to
ourselves or Drs. Leapman and Carroll. However, such dif-
ferences generally represent a greater issue for research
than for clinical recommendations.
The major area of disagreement between the respon-
dents focused on how shared decision-making should be
performed; in particular, whether formal decision aids
should be given to patients and whether the key driver
of decision making should be preference or behavior.
Drs. Leapman and Carroll, as well as Dr. Albertsen and
ourselves, focused on behavior rather than preference,
believing that the net benefit of screening will be optimized
by the increased use of active surveillance and limiting
screening in older men. Conversely, Drs. Schröder, and
Barry and Frosch, emphasized the use of preference-
oriented decision aids, whereas Dr. Ilic focused on in-
formed consent based on an in-depth explanation of
current research findings. Dr. Schröder indicates that it is
the patient himself who has to take the initiative and raise
the topic of screening; if he does so, he should be given a
short decision aid that describes, in general terms, the per-
tinent harms and benefits; it is then “the responsibility of
the person at risk” to weigh those pros and cons. Drs. Barry
and Frosch similarly appear to double down on formal
decision aids when challenged. When questioned as to
whether focus should be placed on changing clinician
behavior, rather than assessing preference in the con-
text of fixed clinician behavior, they stated that there is
insufficient consensus that overdiagnosis and over-
treatment is a problem in prostate cancer. They do
not directly provide evidence to support this assertion,
referring instead to the literature on public percep-
tions of screening. We have sympathy for the argu-
ment that lay ideas about cancer complicate efforts to
combat overtreatment. However, we disagree that there is
a lack of consensus on overtreatment or that clinician
behavior is overly resistant to change. The authors cite
two papers on changes in the use of active surveillance
and conclude that results are conflicting. However, the
paper suggesting little progress [61] only includes data
up to 2011. The article including more recent data in-
volved 45 predominately community-based urology
practices in 28 states across all regions of the US and
indicated that the use of active surveillance for low-risk
disease increased from around 10 % in 2000–2009 to
40 % in 2010–2013 [62]. This number is still far too
low and more work needs to be performed to change
practice. We accept that such work is challenging and
that it will meet resistance. However, we would argue
that it will lead to a far greater health gain than a focus
on preferences.
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questions were raised about the value of decision aids.
There is a large number of conflicting decision aids
available: which should we choose and how complex do
they need to be? Can patients really integrate a large
number of risk estimates for different events and are
these estimates evidence based? Drs. Barry and Frosch
tell us, in general terms, about new initiatives to develop
‘certification’ processes for decision aids and suggest that
“innovative ways of communicating risk” will allow pa-
tients to understand the complexities of screening. This
may well be true, but, as they themselves acknowledge,
that leaves us unable to advise our patients at the
current time.
In a question to Drs. Barry and Frosch, who sup-
port preference-oriented decision aids, we used a
breakfast analogy. Eating eggs is associated with bene-
fit (taste, nutrition) and harms (risk of getting egg on
your tie). This trade-off can be posed either in a pref-
erence framework (how does the individual man feel
about the taste and nutritional value of eggs com-
pared to having a smart appearance?) or a behavioral
one (what can a man do to prevent getting egg on
his tie?). Our own view is that, while preference does
indeed play a role, its value is dwarfed by the import-
ance of clinician behavior. Making choices congruent
with preferences does affect quality of life, but its ef-
fect is small compared to, for example, an unneces-
sary radical prostatectomy or using PSA to detect a
cancer in an older man highly unlikely to benefit
from screening. Assessing preferences is also rather
challenging: how will a man know how he will feel
about being impotent or incontinent, or for that mat-
ter, metastatic prostate cancer, if he has never experi-
enced it? Men who initially tell us “I’d rather die
than be impotent” generally report a good overall
quality of life 5 years after treatment, even with erectile
dysfunction; a man who says “I’ll go when god calls me”
may have little idea just how miserable it is to die of pros-
tate cancer.
We also have considerable concerns with proposals,
such as that made by Dr. Ilic, that doctors discuss the nu-
merical results and methodologic limitations of random-
ized screening trials with patients. We note that many
issues in the interpretation of these trials are extremely
complex – contamination, pre- vs. post-randomization
consent, and time-dependent effect sizes to name but
three – with even experts struggling to grasp key points.
Interpretation of trials also requires considerable numer-
ical abilities: take for instance, a risk reduction of 0.11 per
1,000 men or a number needed to screen of 781. It is also
unclear how a man should integrate multiple conflicting
risks and benefits into one discrete choice: agree to or de-
cline a PSA test.It is also interesting that many decision aids present
virtually all possible downstream consequences of a
PSA test such as transient hematospermia from pros-
tate biopsy or pulmonary embolism after surgery. We
note that doing so is far outside typical medical practice.
Is there any other routine screening test for which we have
these types of complex discussions? Take the following
imaginary conversation between a doctor and, for example,
a 55-year-old man presenting for a general health
check: “Mr. Jones, before I draw your blood or put the
cuff around your arm, I should warn you that in the
event you have high cholesterol or high blood pressure,
you may, in the future, need medication, such as a statin
for high cholesterol or a diuretic, ACE-inhibitor, β-blocker,
or calcium channel blocker for high blood pressure. All of
these medications may give you side-effects. These include
tiredness, hypotension, bradycardia, leg pain, vertigo, [list
continues]. The probability of each of these side effects
is as follows, for instance, for atenolol: tiredness (13 %),
hypotension (10 %), bradycardia (8 %), depression (3 %)
[list continues]; for a thiazide diuretic, there are 34
listed adverse effects [74]. On the other hand, medica-
tions reduce the risk of future problems with your heart
and circulatory system. For instance, β-blockers are as-
sociated with a reduced risk of total cardiovascular
disease, mainly stroke, in the order of seven fewer car-
diovascular events per 1,000, compared to placebo
[75], although effects on overall mortality are contro-
versial. You should also know that the different drugs
have not been fully compared to see which is most ef-
fective. So, Mr. Jones shall I go ahead and measure
your cholesterol and blood pressure or not?” Such a
conversation is obviously absurd. We also note that few
doctors, if any, mention even the possibility of urinary
side effects (frequency from diuretics) or erectile dysfunc-
tion (from β-blockers) as a downstream consequence of a
blood pressure measurement, let alone quantify the mag-
nitude of these risks. Yet, exact quantification of urinary
and sexual side effects is seen as pretty much mandatory
for PSA decision aids.Conclusions
In summary, we agree with our expert authors that pros-
tate cancer screening can save lives, that this comes at a
high cost in terms of overtreatment and overdiagnosis,
and that shared decision-making is necessary before ad-
ministering a PSA test. Nevertheless, we disagree with
Drs. Schröder, Barry, and Frosch in that PSA screening
is predominately a matter of preference that should be
addressed by handing out decision aids assessing prefer-
ence. Further, we disagree with Dr. Ilic that it is appropriate
to discuss the results of complex trials with patients consid-
ering a PSA test.
Carlsson et al. BMC Medicine  (2015) 13:288 Page 16 of 17PSA screening is not a single defined intervention: it
can be practiced in numerous different ways and there is
good (if inevitably incomplete) research data to suggest
which would be more helpful and which more harmful. It
is time to end sterile, for-and-against debates and focus on
making sure that contemporary PSA screening practice
follows best evidence.
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